The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.

Inclusion Criteria:

• Signed and dated informed consent obtained before any trial-related activities
• Type 1 diabetes diagnosed and classified according to aetiology
• Duration of type 1 diabetes equal to or more than 12 months
• Glycosylated haemoglobin less than or equal to 12 percent based on analysis from central laboratory
• Able and willing to perform self-blood glucose monitoring

Exclusion Criteria:

• Proliferative retinopathy
• Total basal insulin dose of more than 100 IU per day
• Recurrent major hypoglycaemia - that would interfere with trial participation (as judged by the investigator)
• Known unawareness of hypoglycaemia
• Previous treatment with insulin detemir

According to the Novo Nordisk Disclosure commitment on novonordisk-trials.com